Standard Glass Lining Technology Ltd IPO
IPO Timeline
Category-wise Subscription
| Category | Sub (x) | Offered | Bid For | Amt (Cr)* |
|---|---|---|---|---|
| QIB | — | 14,643,884 (50%) | — | ₹20,501 Cr |
| NII (HNI) | — | 4,393,406 (15%) | — | ₹6,151 Cr |
| Retail | — | 10,251,279 (35%) | — | ₹14,352 Cr |
| Σ Total | — | 29,288,569 (100%) | — | ₹410,040 Cr |
Only available investor categories are shown. Amount is auto-calculated when shares offered and issue price are available.
Issue Details
Minimum Investment (Lot-wise)
| Category | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | 1 | 107 | ₹14,980 |
| Retail (Max) | 13 | 1,391 | ₹194,740 |
| S-HNI (Min) | 14 | 1,498 | ₹209,720 |
| B-HNI (Min) | 67 | 7,169 | ₹1,003,660 |
Financial Statements Amount in ₹ Crores
| Metric | 30 Sep 2024 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|
| Revenue | 312 | 550 | 500 |
| Profit After Tax | 36 | 60 | 53 |
| Net Worth | 448 | 410 | 157 |
| Total Assets | 757 | 665 | 348 |
| Reserves & Surplus | 262 | 389 | 140 |
| Total Borrowing | 174 | 129 | 82 |
Valuation & Key Ratios
Grey Market Premium (GMP)
GMP is an unofficial grey market indicator and does not guarantee actual listing price. Invest at your own risk.
Objects of the Issue
- –
Company Overview
Incorporated in September 2012, Standard Glass Lining Technology Limited is a manufacturer of engineering equipment for the pharmaceutical and chemical sectors in India. The company has the capability to manage the entire production process in-house.
The company provides turnkey solutions, including design, engineering, manufacturing, assembly, installation, and standard operating procedures for pharmaceutical and chemical manufacturers.
The company's product product portfolio includes
- Reaction Systems;
- Storage, Separation and Drying Systems; and
- Plant, Engineering and Services
The company manufactures specialized engineering equipment using glass-lined materials, stainless steel, and nickel alloy.
The company's customer includes Apitoria Pharma Private Limited, Aurobindo Pharma Limited, CCL Food and Beverages Private Limited, Cohance Lifesciences Limited, Cadila Pharmaceutical Limited, Deccan Fine Chemicals (India) Private Limited, Dasami Lab Private Limited, Laurus Labs Limited, Granules India Limited, Macleods Pharmaceuticals Limited, MSN Laboratories Private Limited, Natco Pharma Limited, Honour Lab Limited, Hetero Drugs Limited, Hetero Labs Limited, Hazelo Lab Private Limited, Piramal Pharma Limited, Sanvira Biosciences Private Limited, Suven Pharmaceuticals Limited, Tagros Chemicals India Private Limited, Vamsi Labs Limited and Viyash Life Sciences Private Limited.
The company has eight manufacturing units situated in Hyderabad, Telangana.
The company's sales offices are situated in Vadodara, Gujarat, Ankleshwar, Gujarat, Mumbai, Maharashtra and Vishakhapatnam, Andhra Pradesh and sales team members are in Jhagadia, Gujarat, Chennai, Tamil Nadu, New Delhi, Bengaluru, Karnataka and Vijayawada, Andhra Pradesh with pan-India reach.
As of September 30, 2024, the company had 460 full-time employees and 731 contract labourers.
Competitive Strength
- Specialised engineering equipment manufacturers for the pharmaceutical and chemical sectors.
- Customized and innovative range of products throughout the entire pharmaceutical and chemical manufacturing value chain.
- Strategically located manufacturing facilities with advanced technological capabilities.
- Long term relationships with marquee clientele across sectors.
- Consistent track record of profitable growth.